Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John L. Cantrell is active.

Publication


Featured researches published by John L. Cantrell.


International Journal of Immunopharmacology | 1983

Augmentation of NK activity by Corynebacterium parvum fractions in vivo and in vitro.

Alan Lichtenstein; Aron Bick; John L. Cantrell; Jacob Zighelboim

Biochemically modified whole cell preparations and derived fractions of Corynebacterium parvum (C. parvum) were evaluated for the ability to augment natural killer cell cytoxicity in vivo and in vitro in rats. Unfractionated C. parvum enhanced peritoneal cell (Pc) NK activity in a dose dependent fashion. This activity appeared to be enriched in insoluble light residue material obtained from hot phenol water extraction. Enhancement of Pc cytotoxicity was significantly greater at all time points tested in rats injected with light residue when compared to rats injected with comparable amounts (by dry weight) of unfractionated organisms. In addition, pyridine extractable material and HCl modified preparations were capable of boosting Pc NK activity following intraperitoneal (I.P.) injection. Periodate treatment abrogated C. parvums ability to boost Pc cytotoxicity and insoluble residue material obtained from pyridine extraction was likewise devoid of NK-enhancing properties. Culture of rat spleen cells overnight with unfractionated C. parvum, light residue and pyridine residue materials enhanced NK cytotoxicity whereas HCl and periodate modified whole cell preparations as well as phenol and pyridine extractable material were incapable of boosting cytotoxicity in vitro. In vitro augmentation by culturing with light residue was dependent on the presence of adherent cells in rat spleen cell populations. Pyridine extracts boost cytotoxicity in vivo and have no effect in vitro while the opposite is true of pyridine residue material suggesting different mechanisms of NK augmentation by C. parvum between in vitro and in vivo systems.


Cellular Immunology | 1981

Activation and mechanism of action of suppressor macrophages.

Alan Lichtenstein; Richard I. Murahata; Marilou Terpenning; John L. Cantrell; Jacob Zighelboim

Abstract Intravenous administration of Corynebacterium parvum to alloimmunized mice activates splenic suppressor macrophages that effectively curtail primary and secondary generation of cytotoxic T lymphocytes (CTLs) in vitro . CTL generation was significantly inhibited in suppressed primary cultures by Day 3, the earliest time point that activity is first detected in control cultures. Suppressor macrophages had to be present during the first 24–48 hr of culture to effectively curtail the generation of CTLs. However, if suppressor macrophages were reactivated by 48-hr in vitro culture and then added to primary sensitizations that had been initiated 48 hr previously, they were capable of significant suppression. Suppressor cells produced a soluble factor that mediated the inhibition of CTL generation. The production or action of this factor could not be counteracted by indomethacin.


Biochemical and Biophysical Research Communications | 1982

Different structural requirements of endotoxic glycolipid for tumor regression and endotoxic activity

Ken-ichi Amano; Edgar Ribi; John L. Cantrell

Abstract Endotoxic glycolipid extracted from the heptose-less mutant of Salmonella typhimurium was treated with alkali and acid reagents. The glycolipid freed of all O-ester linked fatty acids by hydroxylamine had lost tumor regression activity and toxicity, whereas a partial removal of O-ester linked fatty acids by mild alkali did not impair with these activities. The glycolipid retained both activities after removal of 2-keto-3-deoxyotonate by sodium acetate (pH 4.5) but was rendered nontoxic while retaining antitumor activity when hydrolyzed by 0.1N HCl whereby 2-keto-3-deoxyoctonate and glycosidic phosphate was split off the glycolipid molecule. Nontoxic and tumor regressive fractions were separated by means of preparative thin layer chromatography of glycolipid hydrolyzed by mild acid. Thus, it was concluded that glycosidic bound phosphate and at least a portion of fatty acids of the lipid A moiety were essential for toxicity, but that this phosphate is not essential for tumor regression activity.


Cancer Research | 1981

Isolation of a nontoxic lipid A fraction containing tumor regression activity.

Kuni Takayama; Edgar Ribi; John L. Cantrell


Cancer Research | 1979

Enhancement of Endotoxic Shock by N-Acetylmuramyl-l-alanyl-(l-seryl)-d-isoglutamine (Muramyl Dipeptide)

Edgar Ribi; John L. Cantrell; Kenneth B. Von Eschen; Steven Marc Schwartzman


Cancer Research | 1979

Antitumor Activity and Lymphoreticular Stimulation Properties of Fractions Isolated from Corynebacterium parvum

John L. Cantrell; Robert W. Wheat


Cancer Research | 1984

Immunotherapy with Biochemically Dissociated Fractions of Propionibacterium acnes in a Murine Ovarian Cancer Model

Jonathan S. Berek; John L. Cantrell; Alan Lichtenstein; Neville F. Hacker; Reba M. Knox; Roberta K. Nieberg; Thanne Poth; Robert M. Elashoff; Leo D. Lagasse; Jacob Zighelboim


Cancer Research | 1978

Intratumor Chemoimmunotherapy with Mitomycin C and Components from Mycobacteria in Regression of Line 10 Tumors in Guinea Pigs

Charles A. McLaughlin; John L. Cantrell; Edgar Ribi; Eugene P. Goldberg


Cancer Research | 1985

Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.

Jonathan S. Berek; Alan Lichtenstein; Reba M. Knox; Tyler Jung; Thanne P. Rose; John L. Cantrell; Jacob Zighelboim


Cancer Research | 1979

Efficacy of Tumor Cell Extracts in Immunotherapy of Murine EL-4 Leukemia

John L. Cantrell; Charles A. McLaughlin; Edgar Ribi

Collaboration


Dive into the John L. Cantrell's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Edgar Ribi

Rocky Mountain Laboratories

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Reba M. Knox

University of California

View shared research outputs
Top Co-Authors

Avatar

Charles A. McLaughlin

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Leo D. Lagasse

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar

Neville F. Hacker

University of New South Wales

View shared research outputs
Top Co-Authors

Avatar

Aron Bick

University of California

View shared research outputs
Top Co-Authors

Avatar

Christopher J. Froelich

NorthShore University HealthSystem

View shared research outputs
Researchain Logo
Decentralizing Knowledge